Stock Events

Stock Events

enGene 

€5.4
0
-€0.5-8.47% Monday 06:07

Statistics

Day High
5.4
Day Low
5.4
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
280.9M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Aug 15
€0.12
Jul 15
€0.11
Jun 15
€0.11
May 15
€0.11
Apr 15
€0.12
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

12JunExpected
Q2 2025
Q3 2025
Q4 2025
Next
-0.62
-0.54
-0.46
-0.38
Expected EPS
-0.4121709174
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2023
2024
2025
0Revenue
-206.39MNet Income

Analyst Ratings

$15.93Average Price Target
The highest estimate is 22.76.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
60%
Hold
40%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow S0N.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other diseases, overlapping with enGene's focus on gene therapy for gastrointestinal diseases.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, which competes directly with enGene's gene therapy technologies.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is known for its work in CRISPR-Cas9 gene editing, a technology that can be applied similarly to enGene's gene delivery platforms.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in the CRISPR gene editing sector, directly competing with enGene's approach to gene therapy.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, similar to enGene's market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, a field closely related to gene therapy, impacting similar therapeutic areas as enGene.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, competing in the broader genetic medicine space with enGene.
uniQure N.V.
QURE
Mkt Cap4.17B
uniQure is involved in developing gene therapies for patients with severe genetic diseases, directly competing with enGene's therapeutic approaches.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO is a biotechnology company specializing in the development of gene therapy products, competing in the same innovative sector as enGene.

About

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Show more...
CEO
ISIN
CA29286M1059
WKN
000A3EXB6

Listings

F
DE
S0N.F
XNAS
US
ENGNW
XNAS
US
ENGN
BOATS
BOATS
ENGN.BOATS

0 Comments

Share your thoughts

FAQ

What is enGene stock price today?▼
The current price of S0N.F is €5.4 EUR — it has decreased by -8.47% in the past 24 hours. Watch enGene stock price performance more closely on the chart.
What is enGene stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange enGene stocks are traded under the ticker S0N.F.
What is enGene market cap?▼
Today enGene has the market capitalization of 280.9M
When is the next enGene earnings date?▼
enGene is going to release the next earnings report on June 12, 2026.
What were enGene earnings last quarter?▼
S0N.F earnings for the last quarter are -0.38 EUR per share, whereas the estimation was -0.48 EUR resulting in a +21.37% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is enGene revenue for the last year?▼
enGene revenue for the last year amounts to 0 EUR.
What is enGene net income for the last year?▼
S0N.F net income for the last year is -206.39M EUR.
Does enGene pay dividends?▼
Yes, S0N.F dividends are paid monthly. The last dividend per share was 0.12 EUR. As of today, Dividend Yield (FWD)% is 0%.
When did enGene complete a stock split?▼
enGene has not had any recent stock splits.